Opinion|Videos|August 7, 2024
Efficacy and Safety of Subcutaneous Infliximab
Author(s)Jean-Frederic Colombel, MD
A key opinion leader analyzes the clinical remission and endoscopic response data from the LIBERTY CD and LIBERTY UC trials for subcutaneous infliximab-dyyb injection, contrasts it with intravenous infliximab, and evaluates the drug's safety and efficacy profile.
Advertisement
- What are the key findings regarding the clinical remission and endoscopic response of subcutaneous infliximab-dyyb injection from the LIBERTY CD and LIBERTY UC trials?
- How does subcutaneous infliximab injection compare to IV infliximab in terms of sustenance of drug levels?
- Are there any clinical advantages of the subcutaneous delivery over the IV route?
- How does the safety profile of subcutaneous infliximab injection compare to IV infliximab?
Advertisement
Related to this article
End-of-study B-Well data show 91% of patients with chronic hepatitis B who achieved functional cure with bepirovirsen maintained it through Week 96.
With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.
Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).
Post hoc phase 2 data show survodutide improved MASH and fibrosis endpoints across all weight loss categories, including patients losing less than 5%.
Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).
Adding spironolactone lowered 3-month home SBP by 7.7 mm Hg vs standard care in 160 stroke survivors with uncontrolled hypertension.
A systolic target below 120 mm Hg lowered major cardiovascular events vs below 140 mm Hg in 4368 patients with prior ischemic stroke or TIA.
Chronic hypertension in pregnancy was tied to 30% higher odds of critical congenital heart disease in a study of 44 million US births.
Advertisement
Advertisement
Trending on HCPLive
1
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
2
Cannabis Use Tied to Higher Odds of Stroke, Cardiovascular Disease
3
AHA 2026: Intensive Blood Pressure Control Reduces Events After Ischemic Stroke
4
STREAM: Statin Discontinuation Noninferior in Older Adults Without CVD
5